OTC label reform focus on areas of agreement with industry urged by NDMA's Soller.
This article was originally published in The Tan Sheet
Executive Summary
FDA OTC LABEL REFORM: POTENTIAL AREAS OF AGREEMENT WITH INDUSTRY INCLUDE order of information, interchangeable terms and bulleted listings, Nonprescription Drug Manufacturers Association Senior VP-Science and Technology William Soller, PhD, said at a Jan. 18 Drug Information Association workshop on OTC drug labeling and consumer communication. Soller suggested that FDA and industry "might center" their initial efforts in reforming OTC drug labeling on these three areas.